• Home
  • NEW DAY MEDICINE
  • 1 (75) 2025
  • 38 -1 (75) 2025 - Gadaeva N.A., Tosheva H.B. - THE LEVEL OF RELATIONSHIP OF KIM-1 AND MARKERS OF ITS RENAL DYSFUNCTION IN CHRONIC HEART FAILURE ON THE DEVELOPMENT OF RHEUMATIC DEFECTS

38 -1 (75) 2025 - Gadaeva N.A., Tosheva H.B. - THE LEVEL OF RELATIONSHIP OF KIM-1 AND MARKERS OF ITS RENAL DYSFUNCTION IN CHRONIC HEART FAILURE ON THE DEVELOPMENT OF RHEUMATIC DEFECTS

THE LEVEL OF RELATIONSHIP OF KIM-1 AND MARKERS OF ITS RENAL DYSFUNCTION IN CHRONIC HEART FAILURE ON THE DEVELOPMENT OF RHEUMATIC DEFECTS

Gadaeva N.A. - Tashkent Medical Academy

Tosheva H.B. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Khotamova R.S. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

In the article, the degree of correlation of KIM-1 and its indicators with other markers of kidney dysfunction in chronic heart failure developed on the basis of rheumatic heart defects and ischemic heart disease was studied. The higher level of its indicators in blood serum in the first group compared to those in the second group confirms that changes in the kidney begin from its proximal tubules. A reliable decrease in KIM-1 after standard treatments containing empagliflozin indicates a positive effect of the drug on renal tubules. Also, this marker, cystatin-S, was found to be reliably correlated with estimated glomerular filtration rate, tumor necrosis factor alpha, interleukin-6, and left ventricular ejection fraction.

Key words: rheumatic defects, chronic heart failure, markers of renal dysfunction.

First page

224

Last page

232

For citation:Gadaeva N.A., Tosheva H.B., Khotamova R.S. - THE LEVEL OF RELATIONSHIP OF KIM-1 AND MARKERS OF ITS RENAL DYSFUNCTION IN CHRONIC HEART FAILURE ON THE DEVELOPMENT OF RHEUMATIC DEFECTS//New Day in Medicine 1(75)2025 224-232 https://https://newdayworldmedicine.com/en/new_day_medicine/1-75-2025

List of References

  1. Andrew A. House, Christoph Wanner, Mark J. Sarnak, Ileana L. Pina, Christopher W. McIntyre, Paul Komenda, Bertram L. Kasiske, Anita Deswal, Christopher R. deFilippi, John G.F. Cleland, Stefan D. Anker, Charles A. Herzog, Michael Cheung, David C. Wheeler, Wolfgang C. Winkelmayerand Peter A. McCullough; for Conference Participants. KDIGO execut i v e conclusions - Kidney International 2019;95:1304-1317.
  2. Bock JS, Gottlieb SS. Cardiorenal syndrome. Circulation. 2010;121:2592-2600.
  3. Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, Proietti G, Barbuzzi S, Nicolosi GL, Tavazzi L, Maggioni AP, Latini R. Tubular damage and worsening renal function in chronic heart failure. //JACC Heart Fail 2013;1:417-424.
  4. Driver TH, Katz R, Ix JH, Magnani JW, Peralta CA, Parikh CR, Fried L, Newman AB, Kritchevsky SB, Sarnak MJ, Shlipak MG, Health ABC Study. Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study. //Am J Kidney Dis 2014;64:49–56.
  5. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. //Heart 2010;96:1297–1302
  6. Di Lullo L, House A, Gorini A, et al. Chronic kidney disease and cardiovascular complications. //Heart Fail Rev. 2015;20:259-272.
  7. Ebner N., Jankowska E.A., Ponikowski P., Lainscak M., Elsner S., Sliziuk V. et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. //Int. J. Cardiol. 2016; 6-12. DOI: 10.1016/j.ijcard.2015.11.178;
  8. Femke Waanders M.D. et al. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial //Am. J. Kidney Dis. 2009;53(1):16-25.
  9. Geng J.; Qiu Y.; Qin Z.; Su B. The Value of Kidney Injury Molecule 1 in Predicting Acute Kidney Injury in Adult Patients: A Systematic Review and Bayesian Meta-Analysis. //J. Transl. Med. 2021; 19.
  10. Go A.S., Mozaffarian D., Roger V.L. et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association //Circulation. 2014;129(3):228-292.
  11. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. //Kidney Int. 2008;73:863-869.
  12. Ichimura et al. Kidney injury molecule-1 (KIM-1), a putativeepithelial cell adhesion molecule containing a novel immunoglobylindomain, is up regulated in renal cells after injury //J. Biol. Chem. 1998;273(7):4135-4142.
  13. Jungbauer C.G., Birner C., Jung B., Buchner S., Lubnow M., von Bary C., Endemann D., Banas B., Mack M., Böger C.A., Riegger G., Luchner A. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome //Eur. J. Heart Fail. 2011;13(10):1104-1110.
  14. Jung S, Bosch A, Kolwelter J, Striepe K, Kannenkeril D, Schuster T, Ott C, Achenbach S, Schmieder RE. Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. //ESC Heart Fail. 2021 Apr;8(2):1562-1570. doi: 10.1002/ehf2.13257. Epub 2021 Feb 9. PMID: 33559346; PMCID: PMC8006684
  15. K. Damman, S. Masson, H. L. Hillege et al., “Clinical outcome of renal tubular damage in chronic heart failure,” //European Heart Journal, 2011;32(21):2705-2712.
  16. Michael H, Prasad D, Anja H-F, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury. //J Am Coll Cardiol. 2011;57:1752-1761.
  17. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. //J Am Soc Nephrol. 2003;14:2534-2543.
  18. McMurray J., McDonagh T., Morrison C.E., et al. Trends in hospitalization for the heart failure in Scotland. 1980-1990 //Eur. Heart J. 1993;14(9):1158-1162.
  19. McNamara D.M. Pharmocogenetics in Heart Failure: Genomic markers of endothelial and neurohumoral function //Congestive Heart Failure. 2004;10:302-308.
  20. Mozaffarian D., Benjamin E.J., Go A.S. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics - 2016 Update: a report from the American Heart Association //Circulation. 2016;135:348-360.

    file

    download